抗PD-1抗体相关神经系统并发症的临床特征与治疗
该单中心回顾性队列研究纳入347例接受抗PD-1单抗治疗的患者,10例(2.9%)出现亚急性神经系统并发症,以神经肌肉病变多见;中位5.5个周期后发生,中位mRS 2.5分,9例改善,1例死亡。
要点
- 抗PD-1治疗中神经系统并发症发生率约2.9%,以神经肌肉病变多见。
- 症状出现时间不可预测,可在中位5.5个周期后发生,进展可能迅速且危及生命。
- 推荐及时识别并停用抗PD-1治疗,部分病例需免疫 rescue 治疗。
核心结论
- 抗PD-1相关神经系统不良事件表型多样,神经肌肉并发症更常见;虽罕见但需警惕,及时停药并可能需免疫治疗。
研究设计与样本
- 单中心回顾性队列研究,纳入2014年9月至12月至2016年5月19日期间接受抗PD-1单抗治疗的347例患者。
主要发现
- 347例中10例(2.9%)出现亚急性神经系统并发症,包括肌病2例、多种神经病4例、小脑性共济失调1例、自身免疫性视网膜病1例、双侧核间性眼肌麻痹1例、头痛1例。
- 并发症发生于中位5.5个周期(范围1-20)后,症状达最大严重程度的时间为1天至超过3个月,中位mRS评分2.5(范围1-5)。
- 5例合并其他系统性免疫介导并发症:甲状腺功能减退3例、结肠炎2例、肝炎1例。
- 治疗包括停用抗PD-1(7例)、皮质类固醇(7例)、静脉免疫球蛋白(3例)、血浆置换(1例);9例改善(中位mRS 2,范围0-6),1例严重坏死性肌病死亡。
临床怎么用
- 对接受抗PD-1治疗的患者,出现亚急性神经系统症状时应考虑药物相关并发症,及时停用抗PD-1治疗。
- 部分病例需使用皮质类固醇、静脉免疫球蛋白或血浆置换等免疫 rescue 治疗。
局限性
- 单中心回顾性研究,样本量小,仅10例神经系统并发症患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Neurological complications are an increasingly recognized consequence of the use of anti-programmed death 1 (PD-1) antibodies in the treatment of solid-organ tumors, with an estimated frequency of 4.2%. To date, the clinical spectrum and optimum treatment approach are not established. OBJECTIVE: To investigate the frequency, clinical spectrum, and optimum treatment approach to neurological complications associated with anti-PD-1 therapy. DESIGN, SETTING, AND PARTICIPANTS: This single-center, retrospective cohort study was conducted from either September or December 2014 (the approval dates of the study drugs by the US Food and Drug Administration) to May 19, 2016. All patients receiving anti-PD-1 monoclonal antibodies were identified using the Mayo Cancer Pharmacy Database. Patients with development of neurological symptoms within 12 months of anti-PD-1 therapy were included. Patients with neurological complications directly attributable to metastatic disease or other concurrent cancer-related treatments were excluded. MAIN OUTCOMES AND MEASURES: Clinical and pathological characteristics, time to development of neurological symptoms, and modified Rankin Scale (mRS) score. RESULTS: Among 347 patients treated with anti-PD1 monoclonal antibodies (pembrolizumab or nivolumab), 10 (2.9%) developed subacute onset of neurological complications. Seven patients were receiving pembrolizumab, and 3 patients were receiving nivolumab. The patients included 8 men and 2 women. Their median age was 71 years (age range, 31-78 years). Neurological complications occurred after a median of 5.5 (range, 1-20) cycles of anti-PD-1 inhibitors. Complications included myopathy (n = 2), varied neuropathies (n = 4), cerebellar ataxia (n = 1), autoimmune retinopathy (n = 1), bilateral internuclear ophthalmoplegia (n = 1), and headache (n = 1). Peripheral neuropathies included axonal and demyelinating polyradiculoneuropathies (n = 2), length-dependent neuropathies (n = 1), and asymmetric vasculitic neuropathy (n = 1). The time to maximum symptom severity varied from 1 day to more than 3 months. The median mRS score was 2.5 (range, 1-5), indicating mild to moderate disability. Five patients experienced other systemic immune-mediated complications, including hypothyroidism (n = 3), colitis (n = 2), and hepatitis (n = 1). Treatment with anti-PD-1 antibodies was discontinued in 7 patients. Treatment included corticosteroids (n = 7), intravenous immunoglobulin (n = 3), and plasma exchange (n = 1). Nine patients improved, with a median mRS score of 2 (range, 0-6). One patient with severe necrotizing myopathy died. CONCLUSIONS AND RELEVANCE: Neurological adverse events associated with anti-PD-1 therapy have a diverse phenotype, with more frequent neuromuscular complications. Although rare, they will likely be encountered with increasing frequency as anti-PD-1 therapy expands to other cancers. The time of onset is unpredictable, and evolution may be rapid and life-threatening. Prompt recognition and discontinuation of anti-PD-1 therapy is recommended. In some cases, immune rescue treatment may be required.
引用
- Kao JC, Liao B, Markovic SN, et al. Neurological Complications Associated With Anti-Programmed Death 1 (PD-1) Antibodies. JAMA Neurol. 2017. PMID: 28873125. doi:10.1001/jamaneurol.2017.1912
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。